{"id":"ct-p53","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"}]},"_chembl":{"chemblId":"CHEMBL3347606","moleculeType":"Small molecule","molecularWeight":"2109.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-P53 is a biosimilar or follow-on biologic targeting PD-L1, a checkpoint protein that tumors use to evade immune surveillance. By blocking PD-L1, the drug releases the brakes on T-cell mediated immunity, allowing the immune system to recognize and attack cancer cells. This mechanism is similar to other PD-L1 inhibitors and is used across multiple solid tumor types.","oneSentence":"CT-P53 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:03.674Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT05572944","phase":"","title":"Formatting the Risk Prediction Models for Never-Smoking Lung Cancer","status":"RECRUITING","sponsor":"Chung Shan Medical University","startDate":"2022-12-15","conditions":"Lung Cancer","enrollment":10000},{"nctId":"NCT05906992","phase":"PHASE3","title":"A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis","status":"RECRUITING","sponsor":"Celltrion","startDate":"2024-01-11","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":512},{"nctId":"NCT03077243","phase":"PHASE2","title":"P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2016-12","conditions":"Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms","enrollment":195},{"nctId":"NCT06159907","phase":"","title":"Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Gynecological Tumors.","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2021-10-27","conditions":"Gynecological Tumors","enrollment":380},{"nctId":"NCT06088030","phase":"PHASE2","title":"Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer","status":"RECRUITING","sponsor":"Yang Li","startDate":"2023-12-13","conditions":"Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations","enrollment":50},{"nctId":"NCT03358017","phase":"PHASE2","title":"Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-05","conditions":"Triple Negative Breast Cancer","enrollment":54},{"nctId":"NCT01302821","phase":"NA","title":"C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer","status":"WITHDRAWN","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-01","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT02309567","phase":"","title":"Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?","status":"COMPLETED","sponsor":"Cumhuriyet University","startDate":"2014-05","conditions":"Lung Neoplasms, Gene, p53","enrollment":146}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ocrelizumab"],"phase":"phase_3","status":"active","brandName":"CT-P53","genericName":"CT-P53","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"CT-P53 is a monoclonal antibody that binds to and inhibits programmed death ligand 1 (PD-L1), blocking its interaction with PD-1 and restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}